Diabetes and obesity drugs show potential to protect against various cancers

A growing body of scientific evidence indicates that popular GLP-1 drugs, widely used to treat diabetes and obesity, may provide protection against various types of cancer. Several studies presented at this year's congress of the American Society of Clinical Oncology (ASCO) in Chicago suggest that patients on these medications experienced a reduced risk of developing cancer and disease progression, along with better survival rates and more favorable responses to certain therapies compared to those not using GLP-1 therapy.

These studies analyzed medical records and real-world clinical data from patients undergoing treatment with semaglutide, tirzepatide, and older GLP-1 medications. While the research was not designed to definitively explain how GLP-1 therapy impacts cancer treatment, investigators propose that mechanisms such as reduced chronic inflammation, regulation of insulin signaling pathways, and potentially direct actions on tumor biology could contribute to this protective effect in cancer patients.

Dr. Elizabeth Susan McDonald from the University of Pennsylvania presented findings from a study involving 110,000 women, which indicated that GLP-1 users had up to a 35% lower risk of developing breast cancer. She noted that while obesity is a known risk factor for certain cancers, the anti-inflammatory effects of GLP-1 therapy are likely significant for cancer prevention.

Further compelling findings emerged from a study of over 12,000 patients, revealing that GLP-1 drug use was associated with a significantly lower likelihood of developing metastatic disease, particularly in lung, breast, colorectal, and liver cancers. Patients with these cancers using GLP-1 therapy showed a 38% to 50% lower risk of disease spread compared to those on other diabetes medications. Similar benefits were observed for endometrial, bladder, prostate, small intestine tumors, and certain hematological malignancies, with users experiencing better overall survival and reduced mortality risk.

“

Chronic inflammation is one of the basic biological mechanisms involved in the development and progression of many cancers.